JP2018078911A5 - - Google Patents

Download PDF

Info

Publication number
JP2018078911A5
JP2018078911A5 JP2018017340A JP2018017340A JP2018078911A5 JP 2018078911 A5 JP2018078911 A5 JP 2018078911A5 JP 2018017340 A JP2018017340 A JP 2018017340A JP 2018017340 A JP2018017340 A JP 2018017340A JP 2018078911 A5 JP2018078911 A5 JP 2018078911A5
Authority
JP
Japan
Prior art keywords
maf
inhibitors
inhibitor
amplification
copy number
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018017340A
Other languages
English (en)
Japanese (ja)
Other versions
JP6636067B2 (ja
JP2018078911A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2018078911A publication Critical patent/JP2018078911A/ja
Publication of JP2018078911A5 publication Critical patent/JP2018078911A5/ja
Application granted granted Critical
Publication of JP6636067B2 publication Critical patent/JP6636067B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018017340A 2012-10-12 2018-02-02 c−MAFを用いた前立腺がん転移の診断、予後診断および処置のための方法 Active JP6636067B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261713318P 2012-10-12 2012-10-12
US61/713,318 2012-10-12

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016048499A Division JP6446381B2 (ja) 2012-10-12 2016-03-11 c−MAFを用いた前立腺がん転移の診断、予後診断および処置のための方法

Publications (3)

Publication Number Publication Date
JP2018078911A JP2018078911A (ja) 2018-05-24
JP2018078911A5 true JP2018078911A5 (https=) 2019-01-17
JP6636067B2 JP6636067B2 (ja) 2020-01-29

Family

ID=49998595

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015536237A Active JP6074049B2 (ja) 2012-10-12 2013-10-09 c−MAFを用いた前立腺がん転移の診断、予後診断および処置のための方法
JP2016048499A Active JP6446381B2 (ja) 2012-10-12 2016-03-11 c−MAFを用いた前立腺がん転移の診断、予後診断および処置のための方法
JP2018017340A Active JP6636067B2 (ja) 2012-10-12 2018-02-02 c−MAFを用いた前立腺がん転移の診断、予後診断および処置のための方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2015536237A Active JP6074049B2 (ja) 2012-10-12 2013-10-09 c−MAFを用いた前立腺がん転移の診断、予後診断および処置のための方法
JP2016048499A Active JP6446381B2 (ja) 2012-10-12 2016-03-11 c−MAFを用いた前立腺がん転移の診断、予後診断および処置のための方法

Country Status (13)

Country Link
US (4) US10114022B2 (https=)
EP (2) EP3553186B1 (https=)
JP (3) JP6074049B2 (https=)
KR (1) KR101872965B1 (https=)
CN (1) CN104995313A (https=)
AU (1) AU2016213773B2 (https=)
BR (1) BR112015008255B1 (https=)
CA (1) CA2888122A1 (https=)
DK (1) DK2906718T3 (https=)
ES (2) ES2906586T3 (https=)
HK (1) HK1213946A1 (https=)
MX (1) MX365421B (https=)
WO (1) WO2014057357A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108192972B (zh) 2010-10-06 2022-09-09 生物医学研究机构基金会 用于乳腺癌转移的诊断、预后和治疗的方法
EP2650682A1 (en) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
BR112014030750A2 (pt) 2012-06-06 2017-08-22 Inst Catalana Recerca Estudis Avancats Método para diagnóstico, prognóstico e tratamento da metástase do câncer pulmonar
ES2906586T3 (es) 2012-10-12 2022-04-19 Inbiomotion Sl Método para el diagnóstico, pronóstico y tratamiento de metástasis de cáncer de próstata
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
WO2014184679A2 (en) * 2013-03-15 2014-11-20 Inbiomotion S.L. Method for the prognosis and treatment of renal cell carcinoma metastasis
US20160040247A1 (en) 2013-03-15 2016-02-11 Fundació Institut De Recerca Biomèdica (Irb Barcelona) Method for the diagnosis, prognosis, and tratment of cancer metastasis
US11206976B2 (en) * 2014-10-16 2021-12-28 New York University Method and system for simultaneous decomposition of multiple hyperspectral datasets and signal recovery of unknown fluorophores in a biochemical system
KR20170093182A (ko) * 2014-12-11 2017-08-14 인바이오모션 에스.엘. 인간 c-maf에 대한 결합 구성원
WO2016209926A1 (en) * 2015-06-22 2016-12-29 Thomas Jefferson University Cancers expressing ccr5 and methods of treatment of same
US11596642B2 (en) * 2016-05-25 2023-03-07 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-MAF status
CZ307369B6 (cs) * 2016-12-22 2018-07-04 České vysoké učení technické v Praze Kombinace pro radionuklidovou terapii pro použití jako léčivo
KR20200104298A (ko) 2017-11-22 2020-09-03 인바이오모션 에스.엘. c-MAF 상태에 기반한 유방암의 요법 치료
TW202012637A (zh) * 2018-04-24 2020-04-01 瑞典商阿斯特捷利康公司 治療癌症之方法
WO2024130224A2 (en) * 2022-12-16 2024-06-20 Purdue Research Foundation Stapled peptides for sensitization of cancer to treatment
CN116287250B (zh) * 2023-01-18 2025-12-16 中山大学附属第七医院(深圳) 一种前列腺癌骨转移诊断、治疗和/或预后的标志物及其应用
CN119007946B (zh) * 2024-08-02 2025-02-07 连云港市第二人民医院(连云港市临床肿瘤研究所) 一种用于肿瘤患者的全病程智能化医疗管理系统

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE89314T1 (de) 1985-02-13 1993-05-15 Scios Nova Inc Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen.
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
AU734051B2 (en) 1996-04-05 2001-05-31 Salk Institute For Biological Studies, The Hormone-mediated methods for modulating expression of exogenous genes in mammalian systems, and products related thereto
US6242213B1 (en) 1996-12-23 2001-06-05 Immunex Corporation Isolated DNA molecules encoding RANK-L
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
US6274338B1 (en) 1998-02-24 2001-08-14 President And Fellows Of Harvard College Human c-Maf compositions and methods of use thereof
US6355623B2 (en) 1998-09-24 2002-03-12 Hopital-Sainte-Justine Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage
CN1362947A (zh) 1999-03-15 2002-08-07 Axys药物公司 用作蛋白酶抑制剂的n-氰基甲基酰胺
TW404030B (en) 1999-04-12 2000-09-01 Siliconware Precision Industries Co Ltd Dual-chip semiconductor package device having malposition and the manufacture method thereof
US6287813B1 (en) 1999-04-23 2001-09-11 Cistronics Cell Technology Gmbh Antibiotic-based gene regulation system
WO2001049288A1 (en) 2000-01-06 2001-07-12 Merck Frosst Canada & Co. Novel compounds and compositions as protease inhibitors
ATE348617T1 (de) 2000-02-16 2007-01-15 Astellas Pharma Inc Heilmittel gegen durch endothelin verursachte erkrankungen
US6750015B2 (en) 2000-06-28 2004-06-15 Kathryn B. Horwitz Progesterone receptor-regulated gene expression and methods related thereto
PH12012502440A1 (en) 2001-06-26 2013-06-17 Amgen Inc Antibodies to opgl
AR036375A1 (es) 2001-08-30 2004-09-01 Novartis Ag Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
GB0121033D0 (en) 2001-08-30 2001-10-24 Novartis Ag Organic compounds
KR100485271B1 (ko) 2002-01-16 2005-04-27 메타볼랩(주) 전사인자 c-maf의 전사 활성 억제제로서의 니발레놀및 그를 포함하는 약제학적 조성물
SE0201980D0 (sv) 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
DE10235624A1 (de) 2002-08-02 2004-02-19 Aventis Pharma Deutschland Gmbh Endiandric acid H und ihre Derivate, Verfahren zu ihrer Herstellung und Verwendung derselben
US20050060771A1 (en) 2003-09-11 2005-03-17 Farmer Andrew Alan siRNA encoding constructs and methods for using the same
AU2003286499A1 (en) 2003-10-17 2004-06-06 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Interference with c-maf function in multiple myeloma
JP4579581B2 (ja) 2003-12-08 2010-11-10 株式会社グリーンペプタイド 副甲状腺ホルモン関連タンパク質のhla−a24またはhla−a2結合ペプチド
US20090048117A1 (en) 2003-12-18 2009-02-19 President And Fellows Of Harvard College Modulation of immune system function by modulation of polypeptide arginine methyltransferases
TW200526224A (en) 2003-12-22 2005-08-16 Alcon Inc Short form c-Maf transcription factor antagonists for treatment of glaucoma
JP2007524671A (ja) * 2004-01-21 2007-08-30 カイロン コーポレイション M−csfムテインおよびその使用
WO2005116056A1 (ja) 2004-05-26 2005-12-08 Green Peptide Co., Ltd. 副甲状腺ホルモン関連タンパク質のhla-a24またはhla-a2結合ペプチド
WO2006012221A2 (en) 2004-06-25 2006-02-02 The Regents Of The University Of California Target cell-specific short interfering rna and methods of use thereof
WO2006135436A2 (en) 2004-10-22 2006-12-21 University Of Florida Research Foundation, Inc. Inhibition of gene expression and therapeutic uses thereof
US9134237B2 (en) 2005-09-20 2015-09-15 Janssen Diagnotics, LLC High sensitivity multiparameter method for rare event analysis in a biological sample
ES2886923T3 (es) 2005-09-20 2021-12-21 Menarini Silicon Biosystems Spa Métodos y composición para generar sondas de ADN de secuencia única, marcaje de sondas de ADN y el uso de estas sondas
EP1969000A2 (en) 2005-12-06 2008-09-17 Centre National de la Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
WO2007119606A1 (ja) * 2006-04-05 2007-10-25 Yokohama City University 前立腺癌の予後判定方法及びそのための診断薬
WO2008098351A1 (en) 2007-02-14 2008-08-21 University Health Network Treatment of d-cyclin mediated proliferative diseases and hemotological malignancies
EP1961825A1 (en) 2007-02-26 2008-08-27 INSERM (Institut National de la Santé et de la Recherche Medicale) Method for predicting the occurrence of metastasis in breast cancer patients
CN101796072B (zh) 2007-05-24 2014-09-24 埃博灵克斯股份有限公司 用于治疗骨疾病和病症的针对rank-l的氨基酸序列以及包括其的多肽
US20110123617A1 (en) 2007-10-18 2011-05-26 University Health Network Clioquinol for the treatment of hematological malignancies
CA2726537A1 (en) 2008-06-06 2009-12-10 University Health Network 8-hydroxyquinoline derivatives for the treatment of hematological malignancies
US20100215743A1 (en) 2009-02-25 2010-08-26 Leonard Thomas W Composition and drug delivery of bisphosphonates
CN108192972B (zh) 2010-10-06 2022-09-09 生物医学研究机构基金会 用于乳腺癌转移的诊断、预后和治疗的方法
ES2379918B1 (es) * 2010-10-06 2013-05-10 Fundació Privada Institut De Recerca Biomèdica Método para el diagnóstico, pronóstico y tratamiento de la metástasis de cáncer de mama.
CA2826657A1 (en) 2011-02-04 2012-08-09 Bioarray Therapeutics, Inc. Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment
WO2012115885A1 (en) * 2011-02-22 2012-08-30 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers
EP2650682A1 (en) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
BR112014030750A2 (pt) 2012-06-06 2017-08-22 Inst Catalana Recerca Estudis Avancats Método para diagnóstico, prognóstico e tratamento da metástase do câncer pulmonar
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
ES2906586T3 (es) 2012-10-12 2022-04-19 Inbiomotion Sl Método para el diagnóstico, pronóstico y tratamiento de metástasis de cáncer de próstata
CA2906394A1 (en) 2013-03-15 2014-09-18 Fundacio Institut De Recerca Biomedica (Irb Barcelona) Method for the prognosis and treatment of cancer metastasis
US20160040247A1 (en) 2013-03-15 2016-02-11 Fundació Institut De Recerca Biomèdica (Irb Barcelona) Method for the diagnosis, prognosis, and tratment of cancer metastasis
WO2014184679A2 (en) 2013-03-15 2014-11-20 Inbiomotion S.L. Method for the prognosis and treatment of renal cell carcinoma metastasis
DK3055429T3 (en) 2013-10-09 2019-04-23 Fundacio Inst De Recerca Biomedica Irb Barcelona Procedure for the prognosis and treatment of metastatic bone cancer resulting from breast cancer
CN107073040A (zh) 2014-06-17 2017-08-18 艾基诺米公司 子宫内膜病理状况中的干细胞治疗
KR20170093182A (ko) 2014-12-11 2017-08-14 인바이오모션 에스.엘. 인간 c-maf에 대한 결합 구성원
US11596642B2 (en) 2016-05-25 2023-03-07 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-MAF status
KR20200104298A (ko) 2017-11-22 2020-09-03 인바이오모션 에스.엘. c-MAF 상태에 기반한 유방암의 요법 치료

Similar Documents

Publication Publication Date Title
JP2018078911A5 (https=)
JP2016105731A5 (https=)
JP2016516403A5 (https=)
JP2022125079A (ja) がん転移の予後診断および処置のための方法
JP6430560B2 (ja) 前立腺癌マーカーとしてのホスホジエステラーゼ4d7
JP2016539625A5 (https=)
CN103834729B (zh) 肺癌的多基因预后试验
KR102226219B1 (ko) 폐암 전이의 진단, 예후 및 치료 방법
EP1917528B1 (en) Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
CN108192972B (zh) 用于乳腺癌转移的诊断、预后和治疗的方法
AU2014333513B2 (en) Method for the prognosis and treatment of metastasizing cancer of the bone originating from breast cancer
JP2013541339A5 (https=)
JP2015521050A5 (https=)
Wang et al. Heterogeneity in signaling pathways of gastroenteropancreatic neuroendocrine tumors: a critical look at notch signaling pathway
JP2019523641A5 (https=)
KR20150122731A (ko) 암 전이의 예후 및 치료 방법
EP3140427A2 (en) Biomarkers for response to pi3k inhibitors
CN104995313A (zh) 使用c-maf的前列腺癌转移的诊断、预后和治疗的方法
JP2012522756A5 (https=)
Zhang et al. Parathyroid hormone-related protein inhibits DKK1 expression through c-Jun-mediated inhibition of β-catenin activation of the DKK1 promoter in prostate cancer
JP2008512984A5 (https=)
JP5918694B2 (ja) 前立腺がんのマーカーとしてのホスホジエステラーゼ9a
CN102089445A (zh) G蛋白偶联受体相关物质和方法
JP7503864B2 (ja) 免疫抗がん療法に対するバイオマーカーおよびその用途
KR102528973B1 (ko) 면역항암요법에 대한 바이오마커 및 이의 용도